Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | UBE2N | P61088 | 1/20 | 0.37 |
| ▸ | SLC22A4 | Q9H015 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12031568 | 0.81 | GAA (0.45) | KDM3BKMT2AADORA2AGAA | |
| SCHEMBL2491527 | 0.77 | KDM3B (1.00) | KDM3BKMT2ATDP1KDM4EGAA | |
| SCHEMBL12872720 | 0.75 | KDM3B (0.62) | KDM3BKMT2ATDP1MEN1RXFP1 | |
| SCHEMBL1810204 | 0.71 | KMT2A (0.61) | KDM3BKMT2ATDP1MEN1KDM4E | |
| SCHEMBL18689585 | 0.69 | KDM3B (0.46) | KDM3BKMT2ATDP1UBE2NCTDSP1 | |
| SCHEMBL14094104 | 0.69 | KDM3B (0.46) | KDM3BKMT2ATDP1MEN1GAA | |
| SCHEMBL25418259 | 0.66 | ATAD2 (0.60) | KDM3BKMT2ATDP1UBE2NCTDSP1 | |
| SCHEMBL25450 | 0.66 | — | — | |
| SCHEMBL9654185 | 0.66 | KDM3B (0.50) | KDM3BKMT2ATDP1UBE2NSLC22A4 | |
| SCHEMBL28408957 | 0.65 | ALDH1A1 (0.41) | KDM3BTDP1UBE2NTP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | CYP4F2, ACR, CYP4F3 | KDM3B 2968/4885KMT2A 4174/4885TDP1 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.